BIOINFORMATICS APPLICATIONS NOTE
|
|
|
- Abigayle Wilkinson
- 10 years ago
- Views:
Transcription
1 BIOINFORMATICS APPLICATIONS NOTE Vol. 23 no , pages doi: /bioinformatics/btl675 Databases and ontologies The ESID Online Database network D. Guzman 1,2, D. Veit 1, V. Knerr 2, G. Kindle 1, B. Gathmann 1, A. M. Eades-Perner 1 and B. Grimbacher 2, 1 Department of Rheumatology and Clinical Immunology, University Hospital Freiburg, Germany and 2 Department of Clinical Immunology and Molecular Pathology, Royal Free Hospital, University College London, UK Received on July 19, 2006; revised on December 15, 2006; accepted on January 4, 2007 Advance Access publication January 19, 2007 Associate Editor: Charlie Hodgman ABSTRACT Summary: Primary immunodeficiencies (PIDs) belong to the group of rare diseases. The European Society for Immunodeficiencies (ESID), is establishing an innovative European patient and research database network for continuous long-term documentation of patients, in order to improve the diagnosis, classification, prognosis and therapy of PIDs. The ESID Online Database is a web-based system aimed at data storage, data entry, reporting and the import of pre-existing data sources in an enterprise business-to-business integration (B2B). The online database is based on Java 2 Enterprise System (J2EE) with high-standard security features, which comply with data protection laws and the demands of a modern research platform. Availability: The ESID Online Database is accessible via the official website ( Contact: [email protected] Supplementary information: Supplementary data are available at Bioinformatics online. Primary immunodeficiencies (PIDs) are a group of rare diseases, which usually are the product of genetic defects of the immune system and its development. They represent a key area of study in immunology, providing a better understanding of the immunological pathways, their functions and development. To date, 4100 different forms of PIDs have been identified to the molecular level (Shearer and Fischer, 2006). The main approach of identifying the genetic defect, is generating abundant and complex data from different sources, such as knockout mice experiments, genetic diagnosis and case reports. This information is mainly deposited and annotated in peer-reviewed databases, such as OMIM ( nlm.nih.gov/omim). While these databases offer a good description of the molecular defect, the correlation with the clinical phenotype is usually poor and limited only to specific case reports. In addition, the clinical phenotype resulting from a given genotype can be quite variable, depending upon many heterogeneous factors. Thus, this relation between genetic and clinical phenotype cannot be assumed to be linear, but is instead a complex expression of molecular defects regulated by endogenous and exogenous factors, which can lead to a complex set of phenotypic features (Buckley, 2005). This overall *To whom correspondence should be addressed. complexity can be addressed by filling in the existing gap in the clinical phenotype information for PIDs. Given the complexity and low prevalence of PIDs, only through transnational collaborations can sufficient patient numbers be obtained to perform adequate research. The European Society for Immunodeficiencies (ESID), which is a non-profit organization facilitating research on PIDs, has established a European patient and research database network for continuous longterm documentation of patients in order to provide a good platform for scientific research, filling the gap between the generated fundamental knowledge on PIDs and the actual healthcare services delivered to the patients. This secure database network, which is compliant with data protection and international ethics requirements, comprises several novel features and standards for clinical research databases. The ESID Online Database consists of 206 disease-specific registries. The complete set of registries share a common dataset, which is called Core Dataset, handling non-identifying basic patient data, diagnosis, quality of life, therapy, transplantation and laboratory information. In addition to the Core Dataset, extended disease-specific datasets are being continuously developed. To date 30 registries include disease-specific extended datasets. The additional information provided by these extended datasets comprise among others aetiology, genetic cause, infection history, additional diagnoses, collected samples, biopsies and surgery events, clinical and additional investigation analyses. The components of the system used by the ESID Online Database aim at data storage, data entry, reporting and the integration of pre-existing data sources within an enterprise business-to-business integration (B2B) based on Java 2 Enterprise System (J2EE) [Supplementary Material, Fig. 1]. For the data storage component, MySQL MaxDB TM ( is used. The access to the database is carried out using a Java Database Connectivity interface, JDBC TM ( As J2EE application server, Sun Java TM System Application Server ( xml) is used. The central component of the system is the Toolwerk Enterprise Integration and Development Platform Application (EIDP) ( EIDP is a multitier Java Enterprise Development Platform which provides XML programming interfaces to the different components of a J2EE system, i.e. web tier, EJB tier and services tier. As with the web interface, the EJB tier provides the developer with specific 654 ß The Author Published by Oxford University Press. All rights reserved. For Permissions, please [email protected]
2 The ESID Online Database network Fig. 1. Screenshot from the ESID Core Dataset user interface, showing the core dataset module. This interface is accessible via a secure login procedure and allows the manual entry of clinical patient data. All available registries are disease specific and access to the patient data is filtered through a central identification number. functionalities for accessing databases, services and legacy systems. It is even possible to connect different EIDPs together in order to develop complex, secure and high data protection standard systems. The services tier offers specific functionalities for developing the exchange of huge datasets. This tier infrastructure is based on the core of SOAP, but implements its own structures for batch processing. A service builder Java library is available for the development of the clients. The service tier uses the EIDP core system (EJB tier) to access the different data sources [Supplementary Material, Figs 2 and 3]. The ESID Online Database can be accessed using a standard web browser. The access through web browsers is controlled through a user name and password combination. No additional technical prerequisites or plug-ins are required. Communication with other systems is either implemented via SOAP web services calling the EIDP services tier or proprietary communication models when required, where the source database can be accessed through the main EJB tier (plain JDBC, pool connections, other EIDPs or legacy systems) [Supplementary Material, Fig. 4]. All the B2B integration and normal end-user access is only implemented via SSL/TLS encryption. The central server of the ESID Online Database is physically hosted within the secure server network of the IT Centre of the University Hospital Freiburg, Germany. All the registries within the ESID Online Database are managed through multiple entities [Supplementary Material, Tables 1 7]. The complete set of entities is compliant with the PID list of the International Union of Immunological Societies (Notarangelo et al., 2006). With this entity separation, the patients and the data contained are specific to one disease and cannot be accessed through a different application entity. Despite this separation at the application level, the system uses onecommondatabasescheme[supplementarymaterial,fig.5]. The ESID Online Database has an intuitive web interface. A series of web forms are accessible through a side menu containing patient-specific data, which is sorted according to dates where applicable, allowing the documentation of static and follow-up data (Fig. 1). The ESID Online Database uses a complex and secure permission grant system, which regulates the access to the system resources. Every user is assigned at least a role which controls the display of contents and methods for querying the database. In addition, specific centre and sub-centre codes are also generated, filtering the list of patients available for querying and documenting. The ESID Online Database also implements advanced logic for more specific tasks, e.g. charts and report generation, search modules, mutation validation, calculations, integration with external databases and elaborated data entry functionalities based on graphical representations. All this logic is implemented through Java code and integrated into the main application web tier as standard plain-old Java objects (POJO), providing a standard mechanism, based on servlets, to combine reusable pieces of Java classes with the session variables and the access to EJB resources [Supplementary Material, Fig. 6]. The use of I10 codes ( icd/) for disease events descriptions and MeSH terms (available at for organs and tissues, provides a good platform for the standardized characterization of PIDs, these terms and ontologies are integrated into the web interface, through search functions and forms [Supplementary Material, Fig. 7 and Table 8]. An integration with validated mutation data from the IDbases databases (Riikonen and Vihinen, 1999), is already being implemented, providing cross-linked information to other biological databases, such as Human Genome Database ( OMIM, EMBL ( ac.uk/embl/) and UniProt-Swiss database ( uniprot.org/). ACKNOWLEDGEMENTS The ESID Online Database project is sponsored by companies of the Plasma Protein Therapeutics Association Europe (Baxter, Biotest, Grifols, Kedrion, Octapharma) and funded in part by the European Union, EU Contract SP23-CT , EURO-POLICY-PID. REFERENCES Buckley,R.H. (2005) Variable phenotypic expression of mutations in genes of the immune system. J. Clin. Invest., 115, Notarangelo,L. et al. : International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee (2006) Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, J. Allergy Clin. Immunol., 117, Riikonen,P. and Vihinen,M. (1999) MUTbase: maintenance and analysis of distributed mutation databases. Bioinformatics, 15, Shearer,W.T. and Fischer,A. (2006) The last 80 years in primary immunodeficiency: how far have we come, how far need we go? J. Allergy Clin. Immunol., 117,
3 SUPPLEMENTARY MATERIALS: The ESID Online Database Network Guzman D., Veit D., Knerr V., Kindle G., Gathmann B., Eades-Perner AM., Grimbacher B. Figure 1: Architecture of the interacting components of the EIDP platform used by ESID Online Database. The Web Container (servlet container) includes the web application, the reporting component and the service infrastructure. All components interact with the Core System, which manages the access to different data sources. The Web App Cache component is a specific infrastructure which stores the data during the application workflow. The components Web Application, Reporting, Web Services and Core System are defined through XML programming interfaces, and do not require knowledge of the J2EE framework.
4 Figure 2: I Wizard screenshots from the ESID Online Database. 1. Query interface, allows the users to enter search terms, including the use of SQL wildcards. 2. Search results screen, only one term is allowed to be selected per entry. 3. The selected term is automatically added to the entry field.
5 AG AG AG AG AG AG CSR CSR CSR CSR CSR CSR Agammaglobulinemia, X-linked (BTK) B-cell linker protein deficiency (BLNK / SLP65) Immunoglobulin heavy Mu chain deficiency (IGHM) 79A antigen deficiency Immunoglobulin Lambda-like polypeptide 1 deficiency (IGLL1) Agammaglobulinemias with unknown genetic cause Common variable immunodeficiency (CVID) Secondary hypogammaglobulinemia Selective IgM deficiency Immunoglobulin A deficiency 1, IGAD Immunoglobulin A deficiency 2, TACI-related Secondary selective IgA deficiency Immunoglobulin gene deletions Isolated IgG subclass deficiency Immunoglobulin lambda light chain deficiency Deficiency of specific IgG Transient hypogammaglobulinemia of infancy Thymoma with immunodeficiency ICOS deficiency 19 antigen deficiency BAFF receptor deficiency Caspase 8 deficiency Transcobalamin II deficiency Other Hypogammaglobulinemias 40 antigen deficiency (TNFRSF5) 40 antigen ligand deficiency (154) Activation-induced cytidine deaminase deficiency (AID) Uracil- glycosylase deficiency (UNG) Ectodermal dysplasia, anhidrotic, with immune deficiency (IKK-gamma) CSR defects and HIGM syndromes with unknown genetic cause Table 1: Registries in the ESID Online Database contained in the Predominantly Antibody Diseases category. AG=agammaglobulinemias, =hypogammaglobulinemias, CSR=class switch recombination defects (hyper IgM syndromes).
6 TBM TBM TBM TBM TBM TBP TBP TBP TBP TBP TBP 8 4 ADA PNP HLA HLA HLA HLA TAP TAP ZAP NU DGS CMC CMC OB Recombination-activating gene 1 deficiency (RAG1) Recombination-activating gene 2 deficiency (RAG2) cross-link repair protein 1C deficiency (Artemis) Reticular dysgenesia T-B- SCID with unknown genetic cause Severe combined immunodeficiency, X-linked (SCIDX1) Janus kinase 3 deficiency (JAK3) Interleukin 7 receptor deficiency (IL7R) Protein-tyrosine phosphatase, receptor-type C deficiency (45) Protein-tyrosine phosphatase, receptor-type C deficiency (45) T-B+ SCID with unknown genetic cause 8 antigen alpha polypeptide deficiency (8A) Selective 4 cell deficiency Adenosine deaminase deficiency (ADA) Nucleoside phosphorylase deficiency (NP) Major histocompatibility complex class II transactivator (MHC2TA) Regulatory factor X, ankyrin-repeat containing (RFXANK) Regulatory factor X, 5 (RFX5) Regulatory factor X-associated protein (RFXAP) ATP-binding cassette transporter 1 deficiency (TAP1) ATP-binding cassette transporter 2 deficiency (TAP2) Zeta-chain-associated protein kinase deficiency (ZAP70) 3 antigen gamma subunit deficiency (3G) 3 antigen delta subunit deficiency (3D) 3 antigen epsilon subunit deficiency (3E) 3 deficiency of unknown cause Winged-helix nude deficiency (FOXN1) DiGeorge Syndrome Autoimmune polyendocrinopathy syndrome type I (AIRE) Other CMC Other unclassified T-cell disorders Table 2: Registries in the ESID Online Database contained in the Predominantly T-cell Deficiencies category. TBM=T-B- Severe combined immunodeficiency (SCID), TBP=T-B+ Severe combined immunodeficiency (SCID), 8=8-deficiency, 4=4-deficiency, ADA=ADA-deficiency, PNP=PNP-deficiency, HLA=HLA class II deficiency, TAP=TAP deficiency, ZAP=ZAP deficiency, 3=3-deficiency, NU=NUDE/SCID, DGS=DiGeorge syndrome, CMC=Chronic mucocutaneous candidiasis (CMC), OB=Other unclassified T-cell disorders.
7 CGD Chronic granulomatous disease X-linked (CYBB) CGD Chronic granulomatous disease autosomal recessive cytochrome b-negative (CYBA) CGD Chronic granulomatous disease autosomal recessive cytochrome b-positive type I (NCF1) CGD Chronic granulomatous disease autosomal recessive cytochrome b-positive type II (NCF2) CGD CGD with unknown genetic cause SCN Elastase 2 deficiency (ELA2) SCN Growth factor-independent 1 (GFI1) SCN Granulocyte colony-stimulating factor 3 receptor (CSF3R) SCN X-linked severe congenital neutropenia (WAS) CN Elastase 2 deficiency (ELA2) SD SBDS deficiency AL Partial albinism and immunodeficiency syndrome KS Kostmann syndrome FLH Perforin 1 deficiency (PRF1) FLH Familial hemophagocytic lymphohistiocytosis 3 (UNC13D) FLH Syntaxin 11 deficiency FLH Familial hemophagocytic lymphohistiocytosis with unknown genetic cause GS Griscelli syndrome type 1 (MYO5A) GS Griscelli syndrome type 2 (RAB27A) GS Melanophilin deficiency (MLPH) GS Griscelli syndrome with unknown genetic cause CHS Lysosomal trafficking regulator deficiency (LYST) CHS CHS with unknown genetic cause LAD Leukocyte adhesion deficiency type 1 (ITGB2) LAD Congenital disorder of glycosilation type IIc (FUCT1) LAD Leukocyte adhesion deficiency type 3 MPO Myeloperoxidase deficiency (MPO) AB Actin beta deficiency (ACTB) RAC RAS-related C3 Bolutinum toxin substrate 2 deficiency (RAC2) GD CCAAT/enhancer binding protein epsilon deficiency (CEBPE) NG6 Glucose-6-phosphate dehydrogenase deficiency (G6PD) JP Formyl peptide receptor deficiency PLS Cathepsin C deficiency (CTSC) WHI Chemokine CXC motif receptor 4 deficiency (CXCR4) WHI WHIM syndrome with unknown genetic defect MYC Interferon gamma receptor 1 deficiency (IFNGR1) MYC Interferon gamma receptor 2 deficiency (IFNGR2) MYC Interleukin 12B deficiency (IL12B) MYC Interleukin 12 receptor beta-1 deficiency (IL12RB1)
8 MYC MYC MYC MYC MYC OP Interleukin 18 deficiency (IL18) Interleukin 23 alpha deficiency (IL23A) Signal transducer and activator of transcription 1 deficiency (STAT1) Signal transducer and activator of transcription 5 deficiency (STAT5) Susceptibility to mycobacterial infection and unknown genetic defect Other phagocytic disorders Table 3: Registries in the ESID Online Database contained in the Phagocytic Disorders category. CGD=Chronic granulomatous disease, SCN=Severe congental neutropenia, CN=Cyclic neutropenia, SD=Schwachman-Diamond-syndrome, AL=PID with partial albinism, KS=Kostmann syndrome, FLH=Familial hemophagocytic lymphohistiocytosis syndromes, GS=Griscelli syndrome, CHS=Chediak Higashi syndrome, LAD=Leukocyte adhesion deficiency, MPO=Myeloperoxidase deficiency, AB=Actin beta deficiency, RAC=RAC2-GTPase defect, GD=Specific granule defect, NG6=Neutrophil glucose-6-phosphate dehydrogenase, JP=Localized juvenile peridontitis, PLS=Papillon-Lefevre syndrome, WHI=Warts hypogammaglobulinemia infections and myelokathexis, MYC=Defects with susceptibility to mycobacterial infection, OP=Other phagocytic disorders.
9 MBL Complement component 1, Q subcomponent alpha deficiency (C1QA) Complement component 1, Q subcomponent gamma deficiency (C1QG) Complement component C1r deficiency Complement component 1, s subcomponent deficiency (C1s) Complement component 2 deficiency Complement component 3 deficiency (C3) Complement component 4 deficiency Complement component 5 deficiency Complement component 6 deficiency Complement component 7 deficiency Complement component 8 deficiency Complement component 9 deficiency Properdin P factor complement deficiency (P) Complement factor B deficiency Factor D deficiency I Factor deficiency (IF) Complement factor H deficiency Hereditary Angioedema (C1inh) C3b inactivator deficiency Mannan-binding lectin serine protease 2 deficiency (MASP2) Decay-accelerating factor for complement deficiency (DAF 55) 59 antigen P18-20 deficiency (59) Mannose-binding lectin deficiency Table 4: Registries in the ESID Online Database contained in the Complement Deficiencies category. =Complement deficiency, MBL=Mannose-binding lectin.
10 XLP XLP IGE WAS WAS OST OST OST OST ICF ICF CH SD HP NS NS KB KB KB EV EV Lymphoproliferative syndrome, X-linked (SH2D1A) XLP with unknown genetic cause Hyper-IgE syndrome Ataxia telangiectasia (ATM) AT-like disorder Nijmegen breakage syndrome (NBS1) Bloom syndrome (RECQ2) Fanconi anemia Seckel syndrome -ligase 4, ATP-dependent deficiency (LIG4) Other -breakage disorder Wiskott-Aldrich syndrome with mutations in WASP Wiskott-Aldrich syndrome with unknown genetic cause Osteopetrosis, chloride channel 7 deficiency (CLCN7) Osteopetrosis-associated transmembrane protein 1 deficiency (OSTM1) Osteopetrosis with renal tubular acidosis (CA2) Osteopetrosis, T-cell immune regulator 1 deficiency (TCIRG1) methyl transferase 3B deficiency (DNMT3B) ICF with unknown genetic cause Mitochondrial RNA-processing endoribonuclease deficiency (RMRP) Immunoosseus dysplasia, Schimke type (SMARCAL1) Adaptor-related protein complex 3 beta 1 subunit deficiency (AP3B1) Fc fragment for IgG high affinity receptor Ia defect (GR1A 64) Fc fragment for IgG low affinity receptor IIa defect (GR2A 32) Fc fragment for IgG low affinity receptor IIb defect (GR2B 32) Fc fragment for IgG low affinity receptor IIIa defect (GR3A 32) Fc fragment for IgG low affinity receptor IIIb defect (GR3B 32) Fc fragment for IgG receptor transporter alpha defect (GRT) Serine protease inhibitor Kazal-type 5 deficiency (SPINK5) Netherton syndrome with unknown genetic cause Ectodermal dysplasia, anhidrotic, with immune deficiency (IKK-gamma) Nuclear factor of kappa light chain gene enhancer in B cells inhibitor alpha defect (NFKBIA) Interleukin 1 receptor-associated kinase 4 deficiency (IRAK4) Epidermodysplasia verruciformis gene 1 deficiency (EVER1) Epidermodysplasia verruciformis gene 2 deficiency (EVER2)
11 Table 5: Registries in the ESID Online Database contained in the Other Well Defined PIDs category. XLP=X-linked lymphoproliferative syndrome, IGE=Hyper IgE syndrome, =breakage disorder, WAS=Wiskott-Aldrich syndrome, OST=Osteopetrosis, ICF=Immunodeficiency centromeric instability facial anomalies syndrome, CH=Cartilage hair hypoplasia, SD=Schimke disease, HP=Hermansky-Pudlak syndrome 2, =Fc receptor deficiencies, NS=Netherton syndrome, KB=Defects of TLR/NFkappa-B signalling, EV=Epidermodysplasia verruciformis.
12 ALP ALP ALP ALP ALP APE APE IPX IPX MF PF PF MW CS PYO BLA Tumor necrosis factor receptor superfamily member 6 deficiency (ALPS IA-type) Tumor necrosis factor ligand superfamily member 6 deficiency (ALPS IB-type) Caspase 8 deficiency (ALPS IIB-type) Caspase 10 apoptosis-related cysteine protease deficiency (ALPS IIA-type) ALPS with unknown genetic cause Autoimmune regulator deficiency (AIRE) APECED with unknown genetic cause Foxkhead box P3 deficiency (FOXP3) IPEX with unknown genetic cause Familial mediterranean fever defect (MEFV) Familial periodic fever, autosomal dominant (TRAPS) Hyper IgD syndrome (MVK) CIAS1 gene defect CIAS1 gene defect CIAS1 gene defect Proline/serine/threonine phosphatase-interacting protein 1 deficiency (PSTPIP1) Caspase recruitment domain-containing protein 15 deficiency (CARD15) Table 6: Registries in the ESID Online Database contained in the Autoimmune and immunedysregulation syndromes category. ALP=Autoimmune lymphoproliferative syndrome (ALPS), APE=Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), IPX=Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX), MF=Familial mediterranean fever, PF=Familial periodic fever, MW=Muckle-Wells syndrome, =Familial cold autoinflammatory syndrome, CS=CINCA syndrome, PYO=Pyogenic sterile arthritis pyoderma gangrenosum and acne, BLA=Blau syndrome.
13 I10 Code No. Cases I10 Term J Bronchitis, not specified as acute or chronic J Chronic sinusitis J15 63 Bacterial pneumonia, not elsewhere classified J00 38 Acute nasopharyngitis [common cold] H66 26 Suppurative and unspecified otitis media J47 23 Bronchiectasis H10 21 Conjunctivitis Table 7: Representative I10 terms, describing the infection events of patients affected by CVID in the ESID Online Database. These values are not mutually exclusive, more than one infection event can be documented for a given patient.
Practice parameter. PREFACE The purpose of this Practice Parameter for the Diagnosis and Management of Primary Immunodeficiency is to provide the
Practice parameter Practice parameter for the diagnosis and management of primary immunodeficiency Francisco A. Bonilla, MD, PhD*; I. Leonard Bernstein, MD ; David A. Khan, MD ; Zuhair K. Ballas, MD ;
Immunodeficiency. Introduction
Immunodeficiency Laura Carceles Campbell Lawson Liam Edward O'Hara Chiho Okada Maureen Elizabeth Esme Roach Andrew Forbes Robertson Emma Clare Rogers Introduction Immunodeficiency results from the absence
Autoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
Antibody Structure, and the Generation of B-cell Diversity CHAPTER 4 04/05/15. Different Immunoglobulins
Antibody Structure, and the Generation of B-cell Diversity B cells recognize their antigen without needing an antigen presenting cell CHAPTER 4 Structure of Immunoglobulin G Different Immunoglobulins Differences
PRIMARY IMMUNE DEFICIENCY DISEASES IN AMERICA
PRIMARY IMMUNE DEFICIENCY DISEASES IN AMERICA THE FIRST NATIONAL SURVEY OF PATIENTS AND SPECIALISTS Prepared by: Schulman, Ronca & Bucuvalas, Inc. Provided by an educational grant from Bayer Corporation.
Cord blood Banking Transplant List for One USA Bank - StemCyte www.stemcyte.com/cordblood-banking-transplant-list
Cells4Life is the oldest and largest cord blood storage company in the UK. We are governed by some of the world's most stringent medical laws, and are currently the only stem cell storage company in the
specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
B Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
Severe Combined Immune Deficiency (SCID)
Severe Combined Immune Deficiency (SCID) ASCIA EDUCATION RESOURCES (AER) PATIENT INFORMATION Severe combined immune deficiency (SCID) is the most serious form of primary immune deficiency and is usually
LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES
Introduction to immunology. LESSON 3: ANTIBODIES/BCR/B-CELL RESPONSES Today we will get to know: The antibodies How antibodies are produced, their classes and their maturation processes Antigen recognition
Chapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
Natalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
Selective IgA deficiency (slgad) [email protected] 0800 987 8986 www.piduk.org
Selective IgA deficiency (slgad) [email protected] 0800 987 8986 www.piduk.org About this booklet This booklet provides information on selective IgA deficiency (sigad). It has been produced by the PID UK
Antibody Function & Structure
Antibody Function & Structure Specifically bind to antigens in both the recognition phase (cellular receptors) and during the effector phase (synthesis and secretion) of humoral immunity Serology: the
1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.
Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins
Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
TEMA 10. REACCIONES INMUNITARIAS MEDIADAS POR CÉLULAS.
TEMA 10. REACCIONES INMUNITARIAS MEDIADAS POR CÉLULAS. The nomenclature of cytokines partly reflects their first-described function and also the order of their discovery. There is no single unified nomenclature,
The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
Transient Hypogammaglobulinemia of Infancy. Chapter 7
Transient Hypogammaglobulinemia of Infancy Chapter 7 An unborn baby makes no IgG (antibody) and only slowly starts producing it after birth. However, starting at about the sixth month of pregnancy, the
A Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES JASON CYSTER SECTION 13
SECTION 13 HUMORAL IMMUNE RE- SPONSES: ACTIVATION OF B CELLS AND ANTIBODIES CONTACT INFORMATION Jason Cyster, PhD (Email) READING Basic Immunology: Functions and Disorders of the Immune System. Abbas,
Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation
Identification of rheumatoid arthritis and osterthritis patients by transcriptome-based rule set generation Bering Limited Report generated on September 19, 2014 Contents 1 Dataset summary 2 1.1 Project
Chapter 5: Organization and Expression of Immunoglobulin Genes
Chapter 5: Organization and Expression of Immunoglobulin Genes I. Genetic Model Compatible with Ig Structure A. Two models for Ab structure diversity 1. Germ-line theory: maintained that the genome contributed
The Case of Baby Joe by Kristen L.W. Walton Page 1
The Case of Baby Joe: Chronic Infections in an Infant by Kristen L.W. Walton SPIRE Postdoctoral Fellowship Program University of North Carolina Chapel Hill Part I Background At birth, Baby Joe appeared
Overview. Transcriptional cascades. Amazing aspects of lineage plasticity. Conventional (B2) B cell development
Overview B cell development Transcriptional cascades Amazing aspects of lineage plasticity Conventional (B2) B cell development What happens to an autoreactive B cell? B1 vs B2 cells Key anatomical sites
T Cell Maturation,Activation and Differentiation
T Cell Maturation,Activation and Differentiation Positive Selection- In thymus, permits survival of only those T cells whose TCRs recognize self- MHC molecules (self-mhc restriction) Negative Selection-
CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS
CHAPTER 9 IMMUNOGLOBULIN BIOSYNTHESIS Although the process by which a functional gene for immunoglobulin HEAVY and LIGHT CHAINS is formed is highly unusual, the SYNTHESIS, POST- TRANSLATIONAL PROCESSING
Some terms: An antigen is a molecule or pathogen capable of eliciting an immune response
Overview of the immune system We continue our discussion of protein structure by considering the structure of antibodies. All organisms are continually subject to attack by microorganisms and viruses.
Immune Deficiency Foundation Diagnostic & Clinical Care Guidelines. for Primary Immunodeficiency Diseases
Immune Deficiency Foundation Diagnostic & Clinical Care Guidelines for Primary Immunodeficiency Diseases Readers may redistribute this article to other individuals for non-commercial use, provided the
Basics of Immunology
Basics of Immunology 2 Basics of Immunology What is the immune system? Biological mechanism for identifying and destroying pathogens within a larger organism. Pathogens: agents that cause disease Bacteria,
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO [email protected] Gundersen Health System Center for Cancer and
UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO [email protected] Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE
Core Topic 2. The immune system and how vaccines work
Core Topic 2 The immune system and how vaccines work Learning outcome To be able to describe in outline the immune system and how vaccines work in individuals and populations Learning objectives Explain
HuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody
COMPLEMENT PATHWAYS OF COMPLEMENT ACTIVATION:
COMPLEMENT The term "complement" was coined by Paul Ehrlich to describe the activity in serum, which could "complement" the ability of specific antibody to cause lysis of bacteria. Complement historically
HuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal Antibodies Highly Specific Monoclonal Antibodies in just 8 Weeks PROVEN, HIGHLY SPECIFIC, HIGH AFFINITY ANTIBODIES IN 8 WEEKS WITHOUT HuCAL PLATINUM IMMUNIZATION (Human Combinatorial
Microbiology AN INTRODUCTION EIGHTH EDITION
TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein
On April 4, a group of physicians at the 37th annual
By Ronale Tucker Rhodes, MS Better gene sampling and newer transplant regimens are making stem cell transplantation possible for a host of disease states that previously were rarely considered for this
Disclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
Diseases Treated by Blood Stem Cells
Diseases Treated by Blood Stem Cells This is the only website to group hematopoietic (blood) stem cell treatments according to whether they are standard, in trial, or experimental. (Courtesy of Parents
PRODUCT CODE PRODUCTS NAME QUANTITIY MANUFACTURE EIA4088 IA-2 Ab (min. order 11 kits) DRG RIAE/96R IA-2 Autoantibody 96 tests BIOVENDOR EIA1593 IAA
PRODUCT CODE PRODUCTS NAME QUANTITIY MANUFACTURE EIA4088 IA-2 Ab (min. order 11 kits) DRG RIAE/96R IA-2 Autoantibody 96 tests BIOVENDOR EIA1593 IAA (Insulin Autoantibody) DRG EIA1594 ICA (Intra-Cell Autoantibody)
The Immune System: A Tutorial
The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The
CHAPTER 6 ANTIBODY GENETICS: ISOTYPES, ALLOTYPES, IDIOTYPES
CHAPTER 6 ANTIBODY GENETICS: ISOTYPES, ALLOTYPES, IDIOTYPES See APPENDIX: (3) OUCHTERLONY; (4) AFFINITY CHROMATOGRAPHY Human immunoglobulins are made up of LIGHT and HEAVY chains encoded by a total of
Phone: +44 20 8123 2220 Fax: +44 207 900 3970 [email protected] http://marketpublishers.com
Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012-2020
treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart
Disease Usual phenotype acute leukemia precursor chronic leukemia lymphoma myeloma differentiated Pre- B-cell B-cell Transformed B-cell Plasma cell Ig Surface Surface Secreted Major malignant counterpart
B Cell Generation, Activation & Differentiation. B cell maturation
B Cell Generation, Activation & Differentiation Naïve B cells- have not encountered Ag. Have IgM and IgD on cell surface : have same binding VDJ regions but different constant region leaves bone marrow
Stem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
SCID Pilot Study but first
SCID Pilot Study but first SCID Screening by Immunoassay using the Guthrie Specimen D Janik and K Pass Biggs Lab Intent Develop an immunoassay for SCID that can be used as a first tier screening instrument
Malignant Lymphomas and Plasma Cell Myeloma
Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations
Chapter 3. Immunity and how vaccines work
Chapter 3 Immunity and how vaccines work 3.1 Objectives: To understand and describe the immune system and how vaccines produce immunity To understand the differences between Passive and Active immunity
Guidance for Industry
Guidance for Industry Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
B cell activation and Humoral Immunity
B cell activation and Humoral Immunity Humoral immunity is mediated by secreted antibodies and its physiological function is defense against extracellular microbes (including viruses) and microbial exotoxins.
Auto-inflammatory Syndromes Questions and Answers. Dr. med. Bruno Strebel
Auto-inflammatory Syndromes Questions and Answers Dr. med. Bruno Strebel Question 1 Definition of autoinflammatory syndromes in general? Auto-inflammatory Syndromes Questions and answers 2 Question 1 Definition
Rheumatoid arthritis: an overview. Christine Pham MD
Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching
Applications of Ab Molecules. Chapter 4 Monoclonal Ab (p.99) Chapter 5 Ab genes and Ab Engineering (p.128)
Applications of Ab Molecules Chapter 4 Monoclonal Ab (p.99) Chapter 5 Ab genes and Ab Engineering (p.128) Monoclonal Antibodies Clonal Selection of B Lymphocytes Hybridoma Köhler and Milsten (1975) - continuous
1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family
Am I an Alpha-1 Carrier? 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.
DIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES
DIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES Extracts from a review article by KN North and KJ Jones: Recent advances in diagnosis of the childhood muscular dystrophies Journal of Paediatrics and Child Health
Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model
Vitamin D deficiency exacerbates ischemic cell loss and sensory motor dysfunction in an experimental stroke model Robyn Balden & Farida Sohrabji Texas A&M Health Science Center- College of Medicine ISC
Sickle cell anemia: Altered beta chain Single AA change (#6 Glu to Val) Consequence: Protein polymerizes Change in RBC shape ---> phenotypes
Protein Structure Polypeptide: Protein: Therefore: Example: Single chain of amino acids 1 or more polypeptide chains All polypeptides are proteins Some proteins contain >1 polypeptide Hemoglobin (O 2 binding
Activation and effector functions of HMI
Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ
Pulling the Plug on Cancer Cell Communication. Stephen M. Ansell, MD, PhD Mayo Clinic
Pulling the Plug on Cancer Cell Communication Stephen M. Ansell, MD, PhD Mayo Clinic Why do Waldenstrom s cells need to communicate? Waldenstrom s cells need activating signals to stay alive. WM cells
Reconsideration Code 86386. Reconsideration Code Description Nuclear Matrix Protein 22 (NMP22), qualitative
Calendar Year 2013 Centers for Medicare and Medicaid Services (CMS) New and Reconsidered Clinical Laboratory Fee Schedule (CLFS) Test Codes And Final Payment Determinations Reconsideration Code 86386 Reconsideration
INFORMATION KIT. americordblood.com 866.503.6005
INFORMATION KIT americordblood.com 866.503.6005 QUALITY INNOVATION VALUE AMERICORD S FULL SUITE OF STEM CELL BANKING PRODUCTS CORD BLOOD 2.0 CORD TISSUE BANKING PLACENTA TISSUE BANKING Preserve up to two
Types, production of antibodies and Antibody/antigen interaction
Types, production of antibodies and Antibody/antigen interaction Antibodies Secreted by B lymphocytes Great diversity and specificity: >109 different antibodies; can distinguish between very similar molecules
NORD Guides for Physicians #1. Physician s Guide to. Tyrosinemia. Type 1
NORD Guides for Physicians #1 The National Organization for Rare Disorders Physician s Guide to Tyrosinemia Type 1 The original version of this booklet was made possible by donations in honor of Danielle
How to construct transgenic mice
How to construct transgenic mice Sandra Beer-Hammer Autumn School 2010 Bad Schandau Methods additional genetic information transgenic mouse line gene inactivation gene-deficient knockout mouse line Jak2
Proteins. Protein Trivia. Optimizing electrophoresis
Proteins ELECTROPHORESIS Separation of a charged particle in an electric field Michael A. Pesce, Ph.D Department of Pathology New York-Presbyterian Hospital Columbia University Medical Center Rate of migration
Special report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006
Special report Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006 Gene And Protein The gene that causes the mutation is CCND1 and the protein NP_444284 The mutation deals with the cell
Essentials of Anatomy and Physiology, 5e (Martini/Nath) Chapter 14 The Lymphoid System and Immunity. Multiple-Choice Questions
Essentials of Anatomy and Physiology, 5e (Martini/Nath) Chapter 14 The Lymphoid System and Immunity Multiple-Choice Questions 1) The lymphoid system is composed of A) lymphatic vessels. B) lymph nodes.
Understanding Protein Electrophoresis
Understanding Protein Electrophoresis International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
Module 2: Antibodies and Antigens
Module 2: Antibodies and Antigens Lecture 7: Antibodies and Antigens (part I) Antibodies may be defined as the proteins that recognize and neutralize any microbial toxin or foreign substance such as bacteria
FACULTY OF MEDICAL SCIENCE
Doctor of Philosophy Program in Microbiology FACULTY OF MEDICAL SCIENCE Naresuan University 171 Doctor of Philosophy Program in Microbiology The time is critical now for graduate education and research
Why use passive immunity?
Vaccines Active vs Passive Immunization Active is longer acting and makes memory and effector cells Passive is shorter acting, no memory and no effector cells Both can be obtained through natural processes:
Delivering the power of the world s most successful genomics platform
Delivering the power of the world s most successful genomics platform NextCODE Health is bringing the full power of the world s largest and most successful genomics platform to everyday clinical care NextCODE
Becker Muscular Dystrophy
Muscular Dystrophy A Case Study of Positional Cloning Described by Benjamin Duchenne (1868) X-linked recessive disease causing severe muscular degeneration. 100 % penetrance X d Y affected male Frequency
OKT3. ~ The first mouse monoclonal antibody. used in clinical practice in the field of transplantation ~
g944202 潘 怡 心 OKT3 ~ The first mouse monoclonal antibody used in clinical practice in the field of transplantation ~ As everybody knows, OKT3 is the first mouse monoclonal antibody produced for the treatment
Immunodeficiencies with hypergammaglobulinemia: a review
Review Immunodeficiencies with hypergammaglobulinemia: a review Julia Upton* ABSTRACT Primary immunodeficiencies (PID) can present with recurrent infections, autoimmunity, inflammation, or malignancy and
Gateway Health SM Non-Formulary Prior Authorization Criteria Intravenous Immune Globulin (IVIG)
Gateway Health SM Non-Formulary Prior Authorization Criteria Intravenous Immune Globulin (IVIG) Coverage is provided in the following situations: PARP Approved 6/2015 Coverage is provided for Primary Immunodeficiency
HLA-Cw*0602 associates with a twofold higher prevalence. of positive streptococcal throat swab at the onset of
1 HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study Lotus Mallbris, MD, PhD, Katarina Wolk, MD, Fabio Sánchez
General presentation
Cantacuzino National Institute of Research-Development for Microbiology and Immunology General presentation Cantacuzino National Institute of Research-Development for Microbiology and Immunology (NIRDMIC)
The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015
The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response
CONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES
FURTHER EXPERIENCE WITH SUBCUTANEOUS IMMUNOGLOBULIN THERAPY IN CHILDREN WITH PRIMARY IMMUNE DEFICIENCIES Dr Alison Jones Great Ormond Street Hospital for Children NHS Trust London WC1N 3JH United Kingdom
